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Abstract
Background
The optimal reference range of homeostasis model assessment of insulin resistance
(HOMA-IR) in normal Chinese population has not been clearly defined. Here we address
this issue using the Hong Kong Cardiovascular Risk Factor Prevalence Study (CRISPS), a
prospective population-based cohort study with long-term follow-up.
Material & Methods
In this study, normal glucose tolerance (NGT), impaired fasting glucose (IFG), impaired glu-
cose tolerance (IGT) and type 2 diabetes mellitus (T2DM) were defined according to the
1998 World Health Organization criteria. Dysglycemia referred to IFG, IGT or T2DM. This
study comprised two parts. Part one was a cross-sectional study involving 2,649 Hong
Kong Chinese subjects, aged 25–74 years, at baseline CRISPS-1 (1995–1996). The opti-
mal HOMA-IR cut-offs for dysglycemia and T2DM were determined by the receiver-operat-
ing characteristic (ROC) curve. Part two was a prospective study involving 872 subjects
who had persistent NGT at CRISPS-4 (2010–2012) after 15 years of follow-up.
Results
At baseline, the optimal HOMA-IR cut-offs to identify dysglyceia and T2DM were 1.37
(AUC = 0.735; 95% confidence interval [CI] = 0.713–0.758; Sensitivity [Se] = 65.6%, Speci-
ficity [Sp] = 71.3%] and 1.97 (AUC = 0.807; 95% CI = 0.777–0.886; Se = 65.5%, Sp =
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82.9%) respectively. These cut-offs, derived from the cross-sectional study at baseline, cor-
responded closely to the 75th (1.44) and 90th (2.03) percentiles, respectively, of the HOMA-
IR reference range derived from the prospective study of subjects with persistent NGT.
Conclusions
HOMA-IR cut-offs, of 1.4 and 2.0, which discriminated dysglycemia and T2DM respectively
from NGT in Southern Chinese, can be usefully employed as references in clinical research
involving the assessment of insulin resistance.
Introduction
Insulin resistance mediates a number of cardio-metabolic disorders, and plays a crucial role in
the pathogenesis of the metabolic syndrome [1]. Dysglycemia, on the other hand, is a major
clinical manifestation of insulin resistance. Blood glucose increases when there is insufficient
insulin to overcome the resistance to its metabolic actions in maintaining glucose homeostasis.
Over the years, there have been a number of methods to assess insulin resistance [2]. The
hyperinsulinemic euglycemic glucose clamp, albeit the gold standard technique, is limited by
its complexity, invasiveness, high cost and laborious requirements. The homeostasis model
assessment of insulin resistance (HOMA-IR), on the contrary, provides a convenient and inex-
pensive means of estimating insulin resistance, and the estimates derived have been shown to
correlate well with those derived from the euglycemic clamp [3, 4]. Evaluation of insulin resis-
tance is useful in clinical practice, and even more importantly, in diabetes and metabolic
research. For instance, HOMA-IR had been utilized to identify eligible subjects with insulin
resistance in a recently published, multi-center, randomized, placebo-controlled trial that
assessed the effect of pioglitazone in secondary prevention of cardiovascular events [5].
As in any clinical test, a reference range or cut-off is necessary for discrimination of a disease
from normal physiological conditions. The normal reference range of HOMA-IR in Chinese
population has however not been clearly defined. Certainly, ethnic differences in HOMR-IR
cut-offs exist across different populations [6–9]. In addition, most of these cut-offs were
derived from cross-sectional studies that could be confounded by various limitations. In most
studies, HOMR-IR cut-offs were derived either from the lower boundary of the top quintile
[10], or the 75th or 90th percentiles of HOMR-IR estimates from individuals with normal body
weight and glycemia without metabolic disorders evaluated at a single time point [11–13].
Notably, glycemic status of an individual may change over time. In the Diabetes Prevention
Program Outcomes Study [14], 10 and 13% of subjects with pre-diabetes reverted back to nor-
moglycemia over 5.7 years in control and lifestyle intervention group, respectively. On the
other hand, we previously also reported that 16% of subjects with normal glucose tolerance at
baseline could have deterioration of glycemia over a period of 5.4 years [15]. Taken together,
HOMA-IR reference range or cut-offs obtained from cross-sectional studies can be inaccurate
and limited by the inclusion of a proportion of subjects whose glycemic status may either dete-
riorate or improve after the initial evaluation.We therefore performed this study, using both
cross-sectional and prospective approaches, to establish optimal HOMA-IR cut-offs for identi-
fying dysglycemia and type 2 diabetes mellitus (T2DM), and a normal reference range of
HOMA-IR in Southern Chinese respectively, based on the Hong Kong Cardiovascular Risk
Factor Prevalence Study (CRISPS), a population-based prospective cohort study with 15 years
of follow up, including subjects with normoglycemia throughout this time.
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Materials & Methods
Study Patients
This current study involved subjects from CRISPS, a population-based and long-term prospec-
tive study on the development of cardiovascular risk factors in Hong Kong. The study protocol
was approved by the institutional review board of the University of Hong Kong / Hospital
Authority Hong Kong West Cluster. All subjects gave written informed consent prior to any
study related procedures.
Briefly, 2,895 unrelated Hong Kong Chinese subjects aged between 25 and 74 years were
recruited in CRISPS-1 (1995–1996) through randomly selected telephone numbers and
detailedmetabolic risk assessments were performed at baseline. Subjects were followed up in
CRISPS-2 (2000–2004), CRISPS-3 (2005–2008) and CRISP-4 (2010–2012). Details of medical
history taking, anthropometric and biochemical parameters were describedpreviously [16].
Central obesity was defined as having a waist circumference (WC) of90 cm in men and80
cm in women. Hypertension was defined as blood pressure140/90mmHg or on anti-hyper-
tensive medications. Dyslipidemia was defined as having high fasting triglycerides1.69
mmol/L, low HDL-C<1.04 mmol/L in men or<1.29 mmol/L in women, and high
LDL-C 3.4 mmol/L or taking lipid lowering agents.
All subjects, except those taking anti-diabeticmedications for known T2DM diagnosed by
their family physicians, had a 75g oral glucose tolerance test (OGTT)when they attended
assessment from CRISPS-1 to CRISPS-4. Subjects were categorized as having normal glucose
tolerance (NGT), impaired fasting glucose (IFG), impaired glucose tolerance (IGT), or T2DM
according to theWorld Health Organization (WHO) 1998 diagnostic criteria: IFG = fasting
glucose (FG) 6.1 mmol/L and<7.0 mmol/L; IGT = FG<7.0 mmol/L and 2-hour post
OGTTglucose (2hG) 7.8 mmol/L and<11.1 mmol/L; T2DM = FG7.0 mmol/L or
2hG 11.1 mmol/L [17]. In our study, dysglycemia referred to IFG, IGT or T2DM, and non-
DM referred to NGT, IFG or IGT. Insulin was measured by micro-particle enzyme immunoas-
say (Abbott Laboratories, Tokyo, Japan), and HOMR-IR was calculated using a mathematical
formula as follows [18]:
HOMA-IR = (fasting insulin [μlU/ml] x fasting glucose [mmol/L]) / 22.5
Study Design
This study comprised two parts. Part one was a cross-sectional study to determine the optimal
HOMA-IR cut-offs for the discrimination of dysglycemia from NGT, and T2DM from non-
DM, respectively. All subjects from CRISPS-1, who had valid baseline HOMA-IR values, were
included for analysis. Part two was a prospective study to evaluate the optimal reference range
of HOMA-IR in the normal Chinese population, based on a subgroup of subjects with persis-
tent NGT, which was defined as having NGT at both CRISPS-1 and CRISPS-4, and not identi-
fied with dysglycemia at any point during the 15 years of prospective follow-up.
Statistical Analysis
Data were analyzed using IBM SPSS statistics 23.0. Normally distributed data were presented
as means ± standard deviation (SD). Non-normally distributed data were transformed to nor-
mality by natural logarithm prior to analysis and presented as medians (inter-quartile range).
Changes in cardiovascular risk profiles of subjects were compared with successive HOMA-IR
quartiles (p for trend) using one-way ANOVA for continuous variables or gamma for ordinal
variables as appropriate. Pearson's correlation coefficient (r) was calculated to determine the
strength of association between groups. In the first part of this study, at baseline, the optimal
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HOMA-IR cut-offs to discriminate dysglycemia from NGT, and T2DM from non-DM, respec-
tively, were determined as the point with the maximum Youden index (J) on the receiver-oper-
ating characteristic operation (ROC) curvewith J = sensitivity + specificity—1.The total area
under the ROC curve (AUROC) with 95% confidence interval (CI), sensitivity, specificity, posi-
tive predictive value (PPV) and negative predictive value (NPV) of HOMA-IR values to dis-
criminate dysglycemia fromNGT, and T2DM from non-DM, respectively, were also
calculated. In all analyses, statistical significancewas achieved at p< 0.05.
Results
Part One: Cross-Sectional Analysis
In the first part of this study, a total of 2,649 subjects from CRISPS-1 were included in the
cross-sectional analysis, after exclusion of 246 subjects without complete data or valid
HOMA-IR values. Table 1 shows the demographic and metabolic parameters of subjects based
on their glycemic status (NGT versus dysglycemia). At baseline, the median HOMA-IR of sub-
jects with NGT was 1.00 (0.66–1.48), while those with dysglycemia had a significantly higher
Table 1. Descriptive statistics of subjects by baseline glycemic status at CRISPS1 (N = 2649). Data was present as mean±SD or median (interquartile
range); *Log-transformed before analysis. BMI, body mass index; WC, waist circumference; WHR, waist-hip-ratio; SBP, systolic blood pressure; DBP, dia-
stolic blood pressure; HT, hypertension; FG, fasting glucose; 2hG, 2-hour glucose post OGTT; HOMA-IR, Homeostasis Model Assessment-Insulin Resis-
tance; NGT, normal glucose tolerance; T-Chol, total cholesterol; TG, triglycerides; HDL-C, high density lipoprotein cholesterol; LDL-C; low density
lipoprotein cholesterol.
Variables NGT Dysglycemia p-value
Number 1954 695 —
Age, years 43.3±11.9 53.0±12.4 <0.001
Gender, % women 49.6 53.2 0.057
Smoking (%) 0.009
Never smoke 74.5 74.5 —
Former smoker 5.9 8.9 —
Current smoker 19.6 16.5 —
—
BMI, kg/m2 23.5±3.4 25.8±3.6 <0.001
WC, cm 77.3±9.5 84.5±10.1 <0.001
Central obesity, % 29.2 49.9 <0.001
WHR* 0.82 (0.77–0.88) 0.89 (0.83–0.94) <0.001
—
SBP, mmHg 116±17 130±23 <0.001
DBP, mmHg 73±10 79±12 <0.001
HT, % 11.4 38.3 <0.001
—
FG, mmol/L 5.0±0.4 6.5±2.3 <0.001
2hG*, mmol/L 5.6 (4.8–6.4) 9.1 (8.3–11.6) <0.001
Fasting insulin*, pmol/L 30.6 (20.8–45.8) 45.8 (29.2–68.8) <0.001
HOMA-IR* 1.00 (0.66–1.48) 1.78 (1.06–2.73) <0.001
—
T-Chol, mmol/L 4.98±1.01 5.39±0.97 <0.001
TG*, mmol/L 0.90 (0.70–1.30) 1.30 (0.98–1.99) <0.001
HDL-C, mmol/L 1.29±0.33 1.15±0.31 <0.001
LDL-C, mmol/L 3.18±0.86 3.50±0.87 <0.001
Dyslipidemia, % 58.0 81.3 <0.001
doi:10.1371/journal.pone.0163424.t001
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HOMA-IR of 1.78 (1.06–2.73) (p<0.001). Compared with those with NGT, subjects with dys-
glycemia were older, less likely to be current smokers, more obese with central obesity, more
hypertension and more dyslipidemia (p<0.001).
Pearson’s correlation analysis showed that at baseline, HOMA-IR positively correlated with
age (r = 0.117), BMI (r = 0.470), WC (r = 0.445), SBP (r = 0.290), DBP (r = 0.274); fasting and
2-hour post OGTTplasma glucose concentration (r = 0.358 and 0.375, respectively), total cho-
lesterol (r = 0.121), triglyceride (r = 0.348), LDL-C (r = 0.122), and negatively correlated with
HDL-C (r = -0.265) (all p< 0.001). Table 2 presents the correlation of clinical and biochemical
variables with HOMA-IR when baselineHOMA-IR values at CRISPS-1 were further catego-
rized into quartile groups. Briefly, increasing HOMA-IR quartiles were associated with increas-
ing age and obesity indices, higher blood pressure, greater lipid abnormalities and increasing
glycemia.
The ROC curve of HOMA-IR values to distinguish dysglycemia from NGT, and T2DM
from non-DM, respectively, at baseline is shown in Fig 1. The AUROC (95% CI) was 0.735 for
dysglycemia and 0.807 for T2DM. Based on the maximum Youden index on the ROC curve,
the optimal cut-off points of HOMA-IR to discriminate dysglycemia fromNGT, and T2DM
from non-DM, were 1.37 (Sensitivity 65.6% and specificity 71.3%) and 1.97 (Sensitivity 65.5%
Table 2. Correlation of baseline clinical and biochemical parameters with successive HOMA-IR quartiles at CRISPS1 (N = 2649). Data was present
as means±SD or medians (interquartile range).
Variables HOMA-IR
Q1:0.72 Q2: 0.73–1.13 Q3: 1.14–1.83 Q4:1.84 p for trend
Number 667 664 658 660 —
Gender, % of women 45.0 52.4 51.1 53.9 0.003
Age, years 44.5±12.7 44.5±12.5 45.9±12.5 48.5±12.9 <0.001
Ever smoke, % 33.4 25.4 20.9 22.1 <0.001†
BMI, kg/m2 22.2±2.9 23.1±3.0 24.6±3.1 26.7±3.6 <0.001
WC, cm 74.0 76.3 80.4 86.2 <0.001
Central obesity, % 20.2 24.7 40.9 53.0 <0.001†
WHR* 0.80 (0.76–0.86) 0.82 (0.77–0.88) 0.85 (0.79–0.90) 0.88 (0.82–0.93) <0.001
<0.001
SBP, mmHg 114±18 115±17 120±19 129±21 <0.001
DBP, mmHg 72±10 72±10 76±10 80±11 <0.001
HT (%) 9.7 9.9 18.1 36.1 <0.001†
FG, mmol/L 4.9±0.7 5.1±0.6 5.3±0.8 6.3±2.3 <0.001
2hG*, mmol/L 5.4 (4.5–6.5) 5.7 (4.9–6.9) 6.2 (5.3–7.5) 7.4 (6.0–9.7) <0.001
Fasting insulin*, pmol/L 16.7 (13.2–20.1) 28.5 (25.7–31.9) 42.4 (38.2–47.9) 70.1 (59.7–88.9) <0.001
DM, % 2.4 3.3 7.3 27.0 <0.001†
T-Chol, mmol/L 5.00±1.07 4.94±1.03 5.11±0.94 5.30±0.97 <0.001
TG*, mmol/L 0.80 (0.60–1.16) 0.90 (0.62–1.24) 1.10 (0.80–1.50) 1.36 (1.00–2.00) <0.001
HDL-C, mmol/L 1.36±0.34 1.29±0.33 1.22±0.30 1.13±0.30 <0.001
LDL-C, mmol/L 3.16±0.86 3.14±0.89 3.32±0.84 3.43±0.87 <0.001
Dyslipidemia, % 49.8 57.2 69.1 80.6 <0.001†
†Ordinal gamma test
*Log-transformed before analysis. BMI, body mass index; WC, waist circumference; WHR, waist-hip-ratio; SBP, systolic blood pressure; DBP, diastolic
blood pressure; HT, hypertension; FG, fasting glucose; 2hG, 2-hour glucose post OGTT; HOMA-IR, Homeostasis Model Assessment-Insulin Resistance;
NGT, normal glucose tolerance; T-Chol, total cholesterol; TG, triglycerides; HDL-C, high density lipoprotein cholesterol; LDL-C; low density lipoprotein
cholesterol.
doi:10.1371/journal.pone.0163424.t002
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and specificity 82.9%) respectively (Table 3). If arbitrary cut-off values of 1.40 for dysglycemia
and 2.0 for T2DM were adopted, which were also close to the optimal HOMA-IR cut-offs on
ROC, the sensitivity were 69.1% for dysglycemia and 64.0% for T2DM, and the specificity were
75.8% for dysglycemia and 75.5% for T2DM. The PPV was 55.0% for dysglycemia and 30.3%
for T2DM and the NPV was 85.1% for dysglycemia and 92.6% for T2DM (Table 3).
Part Two: Prospective Analysis
In the second part of our investigation, which was a prospective study to evaluate the optimal
reference range of HOMA-IR in the normal Chinese population, a total of 872 subjects with
persistent NGT after 15 years of follow-up were included for analysis. Baseline characteristics
of these subjects at CRISPS1 are shown in S1 Table. Table 4 presents the HOMA-IR percentiles
at baseline (CRISPS-1) of these subjects with persistent NGT on long-term follow-up. The 2.5th
and 95th HOMA-IR percentiles of this persistent NGT group were 0.274 and 2.446.
Fig 1. The receiver-operating characteristic curves of baseline HOMA-IR for detecting dysglycemia
(dotted line) or type 2 diabetes (solid line).
doi:10.1371/journal.pone.0163424.g001
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Importantly, in these 872 subjects who remained NGT after 15 years of prospective follow-up,
the baseline HOMA-IR values at the 75th and 90th percentiles, the commonly used percentile
thresholds to determine cut-off levels, were 1.440 and 2.028 respectively, and were strikingly
similar to the respective optimal cut-offs for dysglycemia (1.4) and T2DM (2.0) obtained from
the cross-sectional analysis of the data of 2,649 subjects at CRISPS-1.
Discussion
In the present study, using two approaches, involving both cross-sectional and prospective
analyses, we have derived optimal HOMA-IR cut-offs of 1.4 and 2.0, to discriminate dysglyce-
mia from NGT, and T2DM from non-DM, respectively in Southern Chinese. This approach is
Table 3. Optimal cut-off points for baseline HOMA-IR to discriminate dysglycemia from normal glucose tolerance, or type 2 diabetes from non-
diabetes, at baseline (N = 2649).
AUROC (95% CI) Cutoff Sensitivity, % Specificity, % PPV, % NPV, %
Dysglycemia 0.735 (0.713–0.758) 1.37* 65.6 71.3 44.9 85.4
1.40† 69.1 75.8 55.0 85.1
1.50† 63.8 77.7 53.1 84.4
Diabetes 0.807 (0.777–0.886) 1.97* 65.5 82.9 29.8 95.6
2.0† 64.0 75.5 30.3 92.6
2.5† 48.9 91.2 38.1 94.2
3.0† 39.8 95.3 48.4 93.5
*Optimal cut-offs by Youden j index
†Arbitrary value. AUROC, area under the curve of the Receiver Operating Characteristic; PPV, positive predictive value; NPV, negative predictive value.
doi:10.1371/journal.pone.0163424.t003
Table 4. Reference range of HOMA-IR derived from the persistent NGT group* (N = 872).
Percentile HOMA-IR
Persistent NGT Group (N = 872)
2.5th 0.274
5th 0.343
10th 0.424
25th 0.645
50th, median 0.939
70th 1.288
71st 1.314
72nd 1.328
73rd 1.350
74th 1.391
75th 1.440
76th 1.458
80th 1.872
87th 1.872
90th 2.028
91st 2.085
95th 2.446
* Persistent NGT group refers to subjects with NGT at both CRISPS 1 and 4, and were not identified with
DM at any point throughout the study.
doi:10.1371/journal.pone.0163424.t004
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different from the vast majority of studies that derivedHOMA-IR cut-offs from cross-sectional
cohorts at only a single time point.
In our study, HOMA-IR correlated with various metabolic parameters at baseline, including
blood pressure, as previously reported [19, 20] As only 75 subjects were on anti-hypertensive
medications, the relationship betweenHOMA-IR and the control of hypertension could not be
assessed. Previous studies had shown significant ethnic differences in the HOMA-IR cut-offs
between the Asian and theWestern populations.While using the 90th percentile of the non-
obese NGT group as the HOMR-IR cut-off, two Japanese studies suggested the threshold val-
ues for insulin resistance were 1.7 [13], and 1.97 [12] respectively. In another recent Japanese
study involving 2,153 healthy subjects, a reference range for HOMR-IR was established as
between 0.4 and 2.4 [9]. Nonetheless, this reference range for Asians, derived from a cross-sec-
tional study, could be confounded by limitations, since subjects in these cross-sectional cohorts
could develop deterioration or improvement of glycemia over time. In contrast, the strengths
of our study, which comprised both cross-sectional and prospective analyses of our cohort,
together with the availability of OGTTdata in subsequent clinical visits, enable the derivation
of a normal reference range of HOMR-IR based on a super-control group who remained as
persistent NGT after a prospective follow-up of 15 years.
First, in a cross-sectional analysis of more than 2,500 Chinese subjects at baseline, we identi-
fied optimal HOMA-IR cut-offs for discrimination of dysglycemia fromNGT, and T2DM
from non-DM, respectively. Next, from a group of subjects identified to have persistent NGT
during 15 years of prospective follow-up, we defined a normal reference range of HOMA-IR in
Chinese. Interestingly, the two HOMA-IR cut-offs, 1.4 for dysglycemia and 2.0 for T2DM, also
fell onto the 75th and 90th percentile of HOMR-IR distribution values in the persistent NGT
group, which are the commonly used reference points for definition of threshold cut-offs in
previous studies on HOMA-IR [11–13]. Therefore, combining these two different approaches,
we recommend the HOMA-IR cut-offs of 1.4 and 2.0 for discrimination of dysglycemia from
NGT, and T2DM from non-DM, respectively in Chinese.
In the present study, dysglycemia and T2DM were chosen as the outcomes of interest.
Firstly, these are the major clinical manifestations of insulin resistance. Furthermore, the asso-
ciations between dysglycemia and cardiovascular outcomes, mortality and even cancer have
been increasingly recognized [21–23]. The Emerging Risk Factors Collaboration had demon-
strated the graded relationship between fasting glucose and cardiovascular outcome, with every
1 mmol/L rise in fasting glucose at above 5.6 mmol/L increasing the risk of coronary heart dis-
ease by 12% [21]. Similarly, every 1% increment of HbA1c levels had been shown to increase
the risk of cardiovascular disease by at least 20% even in non-diabetic individuals [23]. Insulin
resistance undoubtedly plays a crucial role in mediating the development of dysglycemia and
T2DM. The derivation of optimal HOMA-IR cut-offs to discriminate dysglycemia from NGT,
and T2DM from non-DM, respectively, in Chinese is useful not only in clinical practice, but
more importantly, in diabetes and metabolic research on insulin resistance.
Study Limitations
There were several limitations in our study. First, euglycemic clamp was not performed and
hence there was no comparative gold standard evaluation of insulin resistance for the
HOMA-IR estimates in our study, although previous studies had suggested a high correlation
of insulin resistance values assessed by these two approaches [3]. Second, although HOMA-IR
was evaluated in all subjects at each clinical assessment from CRISPS-1 to CRISPS-4, only a
single glucose/insulinpair was performed at each clinical visit. Third, the diagnosis of T2DM
was not sufficiently rigorous, being based on the use of anti-diabeticmedications, or on the
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findings of only a single OGTT, the results of which are not always reproducible. For those on
anti-diabeticmedications, no information was available on the data upon which the diagnosis
was based by their attending physicians. Lastly, HbA1c was not used for diagnosis of T2DM in
our study, as it was not widely accepted as a diagnostic criterion until 2011 onwards [24].
Nonetheless, using this prospective cohort with 15 years of follow-up, our study had derived
two HOMA-IR cut-offs, of 1.4 and 2.0, to discriminate dysglycemia fromNGT, and T2DM
from non-DM, respectively in Southern Chinese. These cut-off values can serve as useful refer-
ences in clinical research involving the assessment of insulin resistance.
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